Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study

Abstract Anti-angiogenesis offers an important treatment strategy for metastatic breast cancer (MBC). Metronomic chemotherapy (MCT) provides antiangiogenic effects without increased toxicities, making it good partner for antiangiogenic therapy. We conducted the present retrospective study to evaluat...

詳細記述

書誌詳細

出版年:	BMC Cancer
主要な著者:	Jiaxuan Liu, Jiayang Zhang, Huiping Li, Guohong Song, Lijun Di, Hanfang Jiang, Ying Yan, Huan Wang, Jing Wang, Xiaoran Liu, Bin Shao, Qiao Li
フォーマット:	論文
言語:	英語
出版事項:	BMC 2025-01-01
主題:	Metastatic breast cancer Anlotinib Metronomic chemotherapy Anti-angiogenesis Safety
オンライン･アクセス:	https://doi.org/10.1186/s12885-024-13403-2